Ожирение и метаболизм жировой ткани.Появились ли новые терапевтические возможности?

Полный текст:

Список литературы

1. Poirier, P. et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arther. Throm. and Vasc. Biol. 2006; 26:968-976.

2. NIH. Clinical guidelines on identification, evaluation and treatment of overweight and obesity in adults. The evidence report. NIH, NHLBI. June, 1998.

3. Brand, M.D., Esteves, T.C. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab. 2005 Aug; 2(2):85-93.

4. Shin, H.D. et al. The effects of UCP-1 polymorphisms on obesity phenotypes among Korean female subjects. Biochem Biophys Res Commun. 2005 Sep 23; 335(2):624-30.

5. Fisler, J.S., Warden, C.H. Uncoupling proteins, dietary fat and the metabolic syndrome. Nutr Metab (Lond). 2006 Sep 12; 3:38.

6. Klein, J. et al. Adipose tissue as sourse and target for novel therapies. TRENDS in Endocrinology and metabolism 17(1): 26-32.

7. Neel, J.V. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? Am J Hum Genet. 1962 Dec; 14:353-62.

8. Kershaw, E.E. et al. Adipose tissue as endocrine organ. J Clin. Endocrinol. Metab. 2004: 89; 2548-2556.

9. Halaas, J.L. et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995: 269:543.

10. Pelleymounter, M.A. et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269:540.

11. Considine, R.V. et al. Serum immunoreactive-leptin concentrations in normalweight and obese humans. New Eng J Med, 1996 334:292.

12. Clement, K. et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature, 1998. 392:398.

13. Chan, J. L. et al. Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc. Natl. Acad. Sci. U. S. A. 2006:103: 8481-8486.

14. Corrine, K., Welt et al. Recombinant Human Leptin in Women with Hypothalamic Amenorrhea. NEJM 2006, Vol. 351:987-997.

15. Ahima, R. S. et al. Metabolic Actions of Adipocyte Hormones: Focus on Adiponectin. Obesity 2006,14: 9S-15S.

16. Kuller, L.H. et al. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis. 2006 Sep 29.

17. Otsuka, F. et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol. 2006 Sep 19;48(6):1155-62.

18. Sattar, N. et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006 Aug 15;114(7):623-9.

19. Kadowaki, T. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006 Jul; 116(7):1784-92.

20. Steppan, C.M. et al. The current biology of resistin. J. Intern. Med. 2004; 255: 439-447.

21. Kralisch, S. et al. Therapeutic perspectives of adipocytokines. Expert Opin. Pharmacother. 2005; 6: 863-872.

22. McTernan, P.G. et al. Resistin. Curr Opin Lipidol. 2006 Apr; 17(2):170-5.

23. Fukuhara, A. et al. Visfatin: a protein secreted by visceral fat that mimics the effect of insulin. Science 2005; 307: 426 430.

24. Sethi, J.K. et al. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol. Med. 2005; 11: 344-347.

25. Yang, Q. et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 430: 356-362.

26. Yang, Q. et al. Retinol-Binding Protein 4 and Insulin Resistance in Lean, Obese, and Diabetic Subjects. NEJM 2006; 354: 2552-2563.

27. Moller, D.E. et al. Role of TNF - in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. 2000; 11: 212-217.

28. Ofci, F. et al. Effects of human anti- TNF - antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885.

29. Paquot, N. et al. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor. J.Clin. Endocrinol. Metab. 2000; 85: 1316-1319.

30. Engeli, S. et al. Tge adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J, Biochem. Cell Biol. 2003; 35: 807-825.

31. Lamounier-Zepter, V. et al. Mechanisms of obesity-related hypertension. Horm. Metab. Re. 2004; 36: 376-380.

32. Engeli, S. et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362.

33. Vickers, S.P. et al. Cannabinoids and the regulation of ingestive behaviour. Curr Drug Targets 2005; 6(2): 215-233.

34. Kirkham, T.C. Endocannabinoids in the regulation of appetite and body weight. Bejhav. Pharmacol. 2005; 16(5-6): 297-313.

35. Piomelli, D. The endocannabinoid system: a drug discovery perspective. Curr. Opin. Invest. Drugs 2005; 6(7): 672-679.

36. Gelfand, E.V. et al. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the manage,ent of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin. Investig. Drugs 2006; 15(3): 307-315

Для цитирования:

Zalevskaya A.G., Patrakeeva E.M. Ожирение и метаболизм жировой ткани.Появились ли новые терапевтические возможности? Ожирение и метаболизм. 2007;4(1):2-7.

For citation:

., . Ozhirenie i metabolizm zhirovoy tkani.Poyavilis' li novye terapevticheskie vozmozhnosti? Obesity and metabolism. 2007;4(1):2-7. (In Russ.)

Просмотров: 18

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)